NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Forecast, Price & News

$1.27

+0.01 (+0.79%)

(As of 09/27/2023 ET)

Compare

Today's Range: $1.26
▼
$1.29
50-Day Range: $1.26
▼
$1.82
52-Week Range: $1.17
▼
$3.02

Volume: 88,024 shs
Average Volume: 1.12 million shs
Market Capitalization: $84.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.40

CytomX Therapeutics MarketRank™ Forecast

Analyst Rating: Reduce
1.75 Rating Score
Upside/Downside: 88.7% Upside
$2.40 Price Target
Short Interest: Bearish
3.32% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.74
Upright™ Environmental Score
News Sentiment: -0.24
Based on 6 Articles This Week
Insider Trading: Selling Shares
$31,468 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.37) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

808th out of 976 stocks

Pharmaceutical Preparations Industry

376th out of 453 stocks

2.9

Analyst's Opinion

Consensus Rating
CytomX Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $2.40, CytomX Therapeutics has a forecasted upside of 88.7% from its current price of $1.27.
Amount of Analyst Coverage
CytomX Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.32% of the outstanding shares of CytomX Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
CytomX Therapeutics has a short interest ratio ("days to cover") of 8.2.
Change versus previous month
Short interest in CytomX Therapeutics has recently increased by 2.30%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
CytomX Therapeutics does not currently pay a dividend.
Dividend Growth
CytomX Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for CytomX Therapeutics is -0.74.

1.0

News and Social Media Coverage

News Sentiment
CytomX Therapeutics has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,468.00 in company stock.
Percentage Held by Insiders
Only 6.90% of the stock of CytomX Therapeutics is held by insiders.
Percentage Held by Institutions
51.11% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.37) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CytomX Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CytomX Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.

CTMX Price History

30 days | 90 days | 365 days | Advanced Chart

CTMX Stock News Headlines

September 25, 2023 | americanbankingnews.com

Sean A. Mccarthy Sells 14,601 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock

September 7, 2023 | fool.com

CytomX Therapeutics (NASDAQ: CTMX)

September 28, 2023 | Chaikin Analytics (Ad)

Something is Coming for America's Top Stock

This stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.

September 5, 2023 | finance.yahoo.com

CytomX Therapeutics to Present at Upcoming September Investor Conferences

August 28, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on CytomX Therapeutics (CTMX)

August 25, 2023 | finance.yahoo.com

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

August 14, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Hold Rating on CytomX Therapeutics (CTMX)

August 10, 2023 | finance.yahoo.com

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

September 28, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

August 10, 2023 | markets.businessinsider.com

Barclays Remains a Buy on CytomX Therapeutics (CTMX)

August 9, 2023 | finanznachrichten.de

CytomX Therapeutics Inc.: CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Their Hold Rating for CytomX Therapeutics (CTMX)

August 9, 2023 | finance.yahoo.com

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2023 | finance.yahoo.com

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 8, 2023 | benzinga.com

Earnings Preview For CytomX Therapeutics

August 1, 2023 | finance.yahoo.com

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

July 20, 2023 | finanznachrichten.de

CytomX Therapeutics Inc.: CytomX Therapeutics Announces New Employment Inducement Grants

June 30, 2023 | msn.com

Why Is CytomX Therapeutics Stock Shooting Higher Today

June 30, 2023 | markets.businessinsider.com

CytomX Therapeutics (CTMX) Gets a Hold from Mizuho Securities

June 30, 2023 | finance.yahoo.com

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

June 8, 2023 | finance.yahoo.com

CytomX Therapeutics (NASDAQ:CTMX) Is In A Good Position To Deliver On Growth Plans

June 1, 2023 | finance.yahoo.com

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

May 11, 2023 | finance.yahoo.com

CytomX Therapeutics First Quarter 2023 Earnings: Beats Expectations

May 10, 2023 | finance.yahoo.com

Q1 2023 CytomX Therapeutics Inc Earnings Call

May 10, 2023 | markets.businessinsider.com

CytomX Therapeutics (CTMX) Receives a Hold from Mizuho Securities

May 9, 2023 | finance.yahoo.com

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 5, 2023 | finance.yahoo.com

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Are Not Doing Enough For Some Investors

See More Headlines

Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Company Calendar

Last Earnings: 8/08/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CTMX
CUSIP: N/A
CIK: 1501989
Web: www.cytomx.com
Phone: (605) 515-3185
Fax: 650-351-0353
Employees: 116
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.40
High Stock Price Forecast: $3.19
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +88.7%
Consensus Rating: Reduce
Rating Score (0-4): 1.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-99,320,000.00
Net Margins: -84.21%
Pretax Margin: -63.92%
Return on Equity: -666.28%
Return on Assets: -23.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.33
Quick Ratio: 1.33

Sales & Book Value

Annual Sales: $53.16 million
Price / Sales: 1.60
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.30) per share
Price / Book: -0.98

Miscellaneous

Outstanding Shares: 66,770,000
Free Float: 62,161,000
Market Cap: $84.80 million
Optionable: Optionable
Beta: 0.65

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Sean A. McCarthy D.Phil. (Age 56)
DPHIL, Chairman & CEO
Comp: $1.03M

Mr. Lloyd A. Rowland Jr. (Age 66)
J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec.
Comp: $608.72k

Mr. Jeffrey Landau B.S. (Age 45)
M.B.A., Sr. VP, Head of Strategy & Chief Bus. Officer
Comp: $581.68k

Mr. Christopher W. Ogden (Age 39)
Sr. VP of Fin. and Accounting, Principal Financial Officer & Principal Accounting Officer

Dr. Marcia P. Belvin Ph.D.
Sr. VP & Chief Scientific Officer

Dr. Chau Cheng M.B.A.
Ph.D., VP of Investor Relations & Corp. Communications

Ms. Danielle Olander-Moghadassian
Sr. VP & Chief HR Officer

Ms. Leslie Robbins
Sr. VP of Intellectual Property

Dr. Yu-Waye Chu M.D. (Age 55)
Chief Medical Officer

Ms. Dawn Benson
Sr. VP of Quality & Product Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CTMX Stock - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" CTMX shares.
View CTMX analyst ratings or view top-rated stocks.
What is CytomX Therapeutics' stock price forecast for 2023?: 4 brokerages have issued 12 month price targets for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $2.00 to $3.19. On average, they predict the company's stock price to reach $2.40 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price.
View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts.
How have CTMX shares performed in 2023?: CytomX Therapeutics' stock was trading at $1.60 on January 1st, 2023. Since then, CTMX shares have decreased by 20.6% and is now trading at $1.27.
View the best growth stocks for 2023 here.
When is CytomX Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CTMX earnings forecast.
How were CytomX Therapeutics' earnings last quarter?: CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.17. The biotechnology company earned $24.72 million during the quarter, compared to the consensus estimate of $17.38 million. CytomX Therapeutics had a negative net margin of 84.21% and a negative trailing twelve-month return on equity of 666.28%.
What ETF holds CytomX Therapeutics' stock ?: Formidable ETF holds 318,111 shares of CTMX stock, representing 1.80% of its portfolio.
What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?: 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

What other stocks do shareholders of CytomX Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).
What is CytomX Therapeutics' stock symbol?: CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."
Who are CytomX Therapeutics' major shareholders?: CytomX Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.72%), Renaissance Technologies LLC (1.68%), Bronte Capital Management Pty Ltd. (1.39%), Marshall Wace LLP (1.01%), Congress Park Capital LLC (0.16%) and LPL Financial LLC (0.15%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy.
View institutional ownership trends.
How do I buy shares of CytomX Therapeutics?: Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CytomX Therapeutics' stock price today?: One share of CTMX stock can currently be purchased for approximately $1.27.
How much money does CytomX Therapeutics make?: CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $84.80 million and generates $53.16 million in revenue each year. The biotechnology company earns $-99,320,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.
How many employees does CytomX Therapeutics have?: The company employs 116 workers across the globe.
How can I contact CytomX Therapeutics?: CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.

This page (NASDAQ:CTMX) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial